These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31924201)

  • 1. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer.
    Shin S; Choi YS; Jung JJ; Im Y; Shin SH; Kang D; Cho JH; Kim HK; Kim J; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Lee G; Cho J; Lee HY; Park HY
    Respir Res; 2020 Jan; 21(1):13. PubMed ID: 31924201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
    Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer.
    Cho JH; Kim J; Kim K; Shim YM; Kim HK; Choi YS
    World J Surg; 2012 May; 36(5):1199-1205. PubMed ID: 22374538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
    Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Evaluation of Lung Function in Patients With Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy.
    Torre-Bouscoulet L; Arroyo-Hernández M; Martínez-Briseño D; Muñoz-Montaño WR; Gochicoa-Rangel L; Bacon-Fonseca L; Pérez-Padilla R; Vergara E; García-Sancho C; Lozano-Ruiz F; Fernández-Plata R; Guzmán-Barragán A; Arrieta O
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):910-918. PubMed ID: 29976503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?
    Leo F; Solli P; Spaggiari L; Veronesi G; de Braud F; Leon ME; Pastorino U
    Ann Thorac Surg; 2004 Jan; 77(1):260-5; discussion 265. PubMed ID: 14726074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications.
    Cerfolio RJ; Talati A; Bryant AS
    Ann Thorac Surg; 2009 Sep; 88(3):930-5; discussion 935-6. PubMed ID: 19699923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
    Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
    Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery.
    Margaritora S; Cesario A; Cusumano G; Cafarotti S; Corbo GM; Ferri L; Ceppi M; Meacci E; Valente S; D'Angelillo RM; Russo P; Porziella V; Bonassi S; Pasqua F; Sterzi S; Granone P
    J Thorac Cardiovasc Surg; 2010 Jun; 139(6):1457-63. PubMed ID: 20363001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lung resection on exercise capacity and on carbon monoxide diffusing capacity during exercise.
    Wang JS; Abboud RT; Wang LM
    Chest; 2006 Apr; 129(4):863-72. PubMed ID: 16608931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer.
    Noh JM; Ahn YC; Lee H; Pyo H; Kim B; Oh D; Park H; Lee E; Park K; Ahn JS; Ahn MJ; Sun JM
    Cancer Res Treat; 2015 Oct; 47(4):645-52. PubMed ID: 25687864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
    Connolly JG; Fiasconaro M; Tan KS; Cirelli MA; Jones GD; Caso R; Mansour DE; Dycoco J; No JS; Molena D; Isbell JM; Park BJ; Bott MJ; Jones DR; Rocco G
    J Thorac Cardiovasc Surg; 2022 Aug; 164(2):389-397.e7. PubMed ID: 35086669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
    Takeda S; Funakoshi Y; Kadota Y; Koma M; Maeda H; Kawamura S; Matsubara Y
    Ann Thorac Surg; 2006 Jul; 82(1):232-6. PubMed ID: 16798220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non-Small Cell Lung Cancer.
    Lee TH; Kang BH; Kim HJ; Wu HG; Lee JH
    Cancer Res Treat; 2023 Jul; 55(3):865-874. PubMed ID: 36701844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications: DLCO/VA% is More important than predicted postoperative %DLCO?
    Takeda S
    Ann Thorac Surg; 2010 May; 89(5):1706-7; author reply 1707. PubMed ID: 20417833
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.